Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in March

PHILADELPHIA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
February 20, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress

PHILADELPHIA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
February 13, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights

PHILADELPHIA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
February 05, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in February

PHILADELPHIA, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
January 24, 2018 16:00 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial...
January 04, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors

PHILADELPHIA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
January 03, 2018 08:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment

Company offers outcomes-based rebates and an innovative contracting model that support patient access in the U.S. while aiming to reduce risk and financial burden for payers and treatment centers ...
January 02, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in January

PHILADELPHIA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
December 19, 2017 15:05 ET | Source: Spark Therapeutics, Inc.

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

LUXTURNA is first gene therapy for a genetic disease, first and only pharmacologic treatment for an inherited retinal disease (IRD) and first adeno-associated virus (AAV) vector gene therapy approved...
December 11, 2017 07:45 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

PHILADELPHIA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...